Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Article

Longitudinal Modelling of Body Mass Index from Birth to 14 Years

Chivers P.a · Hands B.b,e · Parker H.a · Beilin L.c · Kendall G.b,d · Bulsara M.e,f

Author affiliations

a School of Health Sciences, The University of Notre Dame Australia, Fremantle, b Centre for Child Health Research, Telethon Institute for Child Health Research, c Department of Medicine and Pharmacology, The University of Western Australia, d School for Nursing and Midwifery, Faculty of Health Sciences, Curtin University of Technology, Perth, e Institute for Health and Rehabilitation Research, The University of Notre Dame Australia, Fremantle, f School of Population Health, The University of Western Australia, Perth, Australia

Corresponding Author

Paola Chivers, School of Health Sciences, The University of Notre Dame Australia, PO Box 1225, Fremantle, Western Australia 6959, Australia, Tel. +61 8 94330-200, Fax -210, pchivers1@nd.edu.au

Related Articles for ""

Obes Facts 2009;2:302–310

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: To examine the tracking of BMI from birth to age 14 years. Participants and Methods: Linear mixed model (LMM) analysis was used to model the trajectories of BMI (n = 1,403). Adiposity rebound was investigated for a subset of individuals (n = 173). Results: Adolescents who were overweight or obese at 14 years followed a different BMI trajectory from birth compared to those of normal weight. There was a difference between weight status groups for the timing of adiposity rebound (p < 0.001) and BMI at nadir (p < 0.001). The LMM depicted a significant difference in rate of change of BMI over time for males and females (p < 0.001), with female BMI increasing at a faster rate, and for weight status groups (p < 0.005), with the obese cohort having the faster increase in BMI over time. BMI at birth was significantly lower for the normal weight cohort compared to the overweight (p = 0.029) and obese (p = 0.019) cohorts. Conclusion: This study introduces a powerful analytic tool, LMM, to model BMI and shows that weight status at 14 years is the result of a distinct path in earlier years. Compared to their normal weight peers, overweight and obese adolescents experience an earlier adiposity rebound, with a higher BMI at rebound.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Article

Published online: September 10, 2009
Issue release date: November 2009

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 1662-4025 (Print)
eISSN: 1662-4033 (Online)

For additional information: http://www.karger.com/OFA

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.